🎉 M&A multiples are live!
Check it out!

Novonesis Valuation Multiples

Discover revenue and EBITDA valuation multiples for Novonesis and other public comps.

See Novonesis Valuation Multiples

Novonesis Overview

About Novonesis

Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.


Founded

2000

HQ

Denmark
Employees

6.8K+

Website

novozymes.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$28.1B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Novonesis Financials

Novonesis has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Novonesis achieved revenue of $336M and an EBITDA of $103M.

Novonesis expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Novonesis valuation multiples based on analyst estimates

Novonesis P&L

FY 2022 FY 2023 FY 2024 LTM NTM
Revenue $281M $329M $336M n/a XXX
Gross Profit $162M $180M $182M XXX XXX
Gross Margin 58% 55% 54% XXX XXX
EBITDA $102M $115M $103M n/a XXX
EBITDA Margin 36% 35% 31% NaN% XXX
Net Profit $59.1M $68.9M $56.7M XXX XXX
Net Margin 21% 21% 17% XXX XXX
Net Debt n/a $33.3M $117M XXX XXX

Financial data powered by Morningstar, Inc.

Novonesis Stock Performance

As of February 10, 2025, Novonesis's stock price is DKK 406 (or $57).

Novonesis has current market cap of DKK 189B (or $26.3B), and EV of DKK 201B (or $28.1B).

See Novonesis trading valuation data

Novonesis Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$28.1B $26.3B XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Novonesis Valuation Multiples

As of February 10, 2025, Novonesis has market cap of $26.3B and EV of $28.1B.

Novonesis's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Novonesis's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Novonesis and 10K+ public comps

Novonesis Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $28.1B XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E n/a XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Novonesis Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Novonesis Valuation Multiples

Novonesis's NTM/LTM revenue growth is n/a

Novonesis's revenue per employee for the last fiscal year averaged $50K, while opex per employee averaged $15K for the same period.

Over next 12 months, Novonesis's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Novonesis's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Novonesis and other 10K+ public comps

Novonesis Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 2% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -10% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $50K XXX XXX XXX XXX
Opex per Employee $15K XXX XXX XXX XXX
S&M Expenses to Revenue 13% XXX XXX XXX XXX
G&A Expenses to Revenue 5% XXX XXX XXX XXX
R&D Expenses to Revenue 11% XXX XXX XXX XXX
Opex to Revenue 29% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Medical Devices
Consumer SaaS
Streaming Platforms
AdTech Software
Climate Tech
GRC Software
Developer Tools

Novonesis Public Comps

See valuation multiples for Novonesis public comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Borouge XXX XXX XXX XXX XXX XXX
Fertiglobe XXX XXX XXX XXX XXX XXX
Akzo Nobel XXX XXX XXX XXX XXX XXX
DSM Firmenich XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Novonesis M&A and Investment Activity

Novonesis acquired  XXX companies to date.

Last acquisition by Novonesis was  XXXXXXXX, XXXXX XXXXX XXXXXX . Novonesis acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Novonesis

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Novonesis

When was Novonesis founded? Novonesis was founded in 2000.
Where is Novonesis headquartered? Novonesis is headquartered in Denmark.
How many employees does Novonesis have? As of today, Novonesis has 6.8K+ employees.
Who is the CEO of Novonesis? Novonesis's CEO is Ms. Ester Baiget.
Is Novonesis publicy listed? Yes, Novonesis is a public company listed on CSE.
What is the stock symbol of Novonesis? Novonesis trades under NSIS B ticker.
When did Novonesis go public? Novonesis went public in 2000.
Who are competitors of Novonesis? Similar companies to Novonesis include e.g. Borouge, Fertiglobe, Akzo Nobel, DSM Firmenich.
What is the current market cap of Novonesis? Novonesis's current market cap is $26.3B
What is the current revenue growth of Novonesis? Novonesis revenue growth between 2023 and 2024 was 2%.
Is Novonesis profitable? Yes, Novonesis is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.